TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,684,560 | -0.2% | 524,000 | +71.4% | 0.04% | -10.0% |
| Q2 2023 | $4,694,461 | -27.5% | 305,629 | +6.2% | 0.04% | -35.5% |
| Q1 2023 | $6,471,676 | +839.3% | 287,758 | +929.0% | 0.06% | +933.3% |
| Q3 2022 | $689,000 | -30.8% | 27,964 | -32.0% | 0.01% | -40.0% |
| Q2 2022 | $996,000 | +250.7% | 41,109 | +273.7% | 0.01% | +233.3% |
| Q1 2022 | $284,000 | -30.2% | 11,000 | -16.0% | 0.00% | -25.0% |
| Q4 2021 | $407,000 | +73.2% | 13,100 | +35.1% | 0.00% | +100.0% |
| Q3 2021 | $235,000 | -26.6% | 9,700 | -55.8% | 0.00% | -33.3% |
| Q2 2021 | $320,000 | -90.4% | 21,960 | -82.1% | 0.00% | -93.3% |
| Q4 2020 | $3,348,000 | – | 122,819 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |